Immunotherapy in Triple-Negative Breast Cancer: Present and Future

被引:0
作者
Isaac Kim
Katherine Sanchez
Heather L. McArthur
David Page
机构
[1] Providence Cancer Institute,Earle A. Chiles Research Institute
[2] Cedars-Sinai Medical Center,undefined
来源
Current Breast Cancer Reports | 2019年 / 11卷
关键词
Breast cancer; Immunotherapy; Triple-negative; Immune checkpoint blockade; PD-L1; IMpassion130;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:259 / 271
页数:12
相关论文
共 830 条
[1]  
Denkert C(2017)Molecular alterations in triple-negative breast cancer - the road to new treatment strategies Lancet 389 2430-2442
[2]  
Liedtke C(2019)The neoepitope landscape of breast cancer: implications for immunotherapy BMC Cancer 19 200-238
[3]  
Tutt A(2015)Classical pathology and mutational load of breast cancer - integration of two worlds J Pathol Clin Res 1 225-250
[4]  
von Minckwitz G(2016)The genomic landscape of breast cancer and its interaction with host immunity Breast 29 241-206
[5]  
Narang P(2019)Tumor mutational load predicts survival after immunotherapy across multiple cancer types Nat Genet 51 202-2608
[6]  
Chen M(2017)Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers Molecular Cancer Therapeutics 16 2598-1550
[7]  
Sharma AA(2014)Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial Ann Oncol 25 1544-271
[8]  
Anderson KS(2015)The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 Ann Oncol 26 259-50
[9]  
Wilson MA(2018)Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy Lancet Oncol 19 40-1360
[10]  
Budczies J(2016)Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review JAMA Oncology. 2 1354-34